Stevanato Group announced a significant expansion of its drug delivery system manufacturing capacity, further strengthening its global footprint to meet the industry’s evolving needs.
As part of its footprint optimisation plan, the Company recently added a state-of-the-art production space for drug delivery devices to its facility in Bad Oeynhausen, Germany. This initiative provides more than 2,500 square metres of advanced manufacturing capacity designed to serve global pharma and biotech partners seeking robust and resilient European supply-chain integration.
The multi-million investment includes installation of an ISO 8 clean-room environment, fully equipped for injection moulding and automated assembly operations. These upgrades enable the site to support both Stevanato Group’s proprietary device production and contract manufacturing services enhancing operational flexibility, scalability and speed-to-market across the company’s drug delivery systems portfolio.
The enhanced Bad Oeynhausen facility plays a pivotal role in advancing the production of key portfolio devices, including the Aidaptus® autoinjector and Alina® pen injector platforms. By integrating the Company’s core capabilities in glass primary packaging, analytical services and equipment manufacturing, Stevanato Group continues to reinforce its position as a trusted partner in enabling safe, effective and patient-centric combination products tailored to individual customer requirements.
“This investment underscores our commitment to advancing self-injection technologies and supporting our customers in delivering better patient outcomes,” said Michele Monico, President of DDS and IVD Business Unit at Stevanato Group. “As demand for drug delivery devices accelerates and patient adoption continues to rise—driven by the need for more convenient, personalized treatment options—expanding our manufacturing capacity is a strategic step to ensure readiness, agility, and innovation across our value chain.”